JP2008500373A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500373A5
JP2008500373A5 JP2007515450A JP2007515450A JP2008500373A5 JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5 JP 2007515450 A JP2007515450 A JP 2007515450A JP 2007515450 A JP2007515450 A JP 2007515450A JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5
Authority
JP
Japan
Prior art keywords
myostatin
preparation
protein
amino acids
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018928 external-priority patent/WO2005115439A2/en
Publication of JP2008500373A publication Critical patent/JP2008500373A/ja
Publication of JP2008500373A5 publication Critical patent/JP2008500373A5/ja
Pending legal-status Critical Current

Links

JP2007515450A 2004-05-27 2005-05-27 ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 Pending JP2008500373A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57506204P 2004-05-27 2004-05-27
PCT/US2005/018928 WO2005115439A2 (en) 2004-05-27 2005-05-27 Cerberus/coco derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2008500373A JP2008500373A (ja) 2008-01-10
JP2008500373A5 true JP2008500373A5 (https=) 2008-07-17

Family

ID=35451405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515450A Pending JP2008500373A (ja) 2004-05-27 2005-05-27 ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用

Country Status (8)

Country Link
US (4) US7316998B2 (https=)
EP (1) EP1755648A2 (https=)
JP (1) JP2008500373A (https=)
KR (1) KR20070026650A (https=)
AU (1) AU2005247508A1 (https=)
CA (1) CA2567810A1 (https=)
IL (1) IL179602A0 (https=)
WO (1) WO2005115439A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045553B2 (en) * 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
SI2049664T1 (sl) 2006-08-11 2012-04-30 Prosensa Technologies Bv Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
CA2671983A1 (en) 2006-12-08 2009-06-19 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
EA018221B1 (ru) * 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
WO2008106478A1 (en) * 2007-02-27 2008-09-04 Lanx, Llc Compositions and methods for modification of target cells and to their uses thereof
US20100150881A1 (en) * 2007-06-01 2010-06-17 Lanx, Inc. Compositions and Methods for Use of Scar Tissue in Repair of Weight Bearing Surfaces
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009105606A1 (en) * 2008-02-21 2009-08-27 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US9149319B2 (en) * 2008-09-23 2015-10-06 Lanx, Llc Methods and compositions for stabilization of a vertebra
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
AU2010260145B2 (en) * 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
AU2010315245B2 (en) 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
DE102010052941A1 (de) * 2010-11-18 2012-05-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutisches Protein
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP3741375A1 (en) * 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
EP4218817A3 (en) * 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
CN109758616B (zh) * 2019-03-05 2021-11-19 中国医学科学院北京协和医院 一种新型促进骨再生材料及其制备方法
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998034951A1 (en) 1997-02-11 1998-08-13 Amrad Operations Pty. Ltd. A new cytokine family and uses thereof
US6610510B1 (en) * 1997-04-29 2003-08-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
US5935852A (en) 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000055193A2 (en) 1999-03-12 2000-09-21 Regeneron Pharmaceuticals, Inc. Human dan/cerberus related protein 6 (dcr6)
AU2002227172A1 (en) 2000-10-19 2002-04-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the cer1 gene
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
GB0111004D0 (en) 2001-05-04 2001-06-27 Univ Sheffield Screening method
US6513196B2 (en) 2001-06-22 2003-02-04 Maytag Corporation Top cover hinge and method for using same
CN1161875C (zh) 2001-07-01 2004-08-11 周符明 开关稳功率电源
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
KR100996226B1 (ko) 2001-10-31 2010-11-24 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
KR20080045764A (ko) 2002-06-14 2008-05-23 신젠타 파티서페이션즈 아게 자일라나제, 이를 암호화하는 핵산, 및 이의 제조 및 사용방법
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
WO2004074460A2 (en) 2003-02-19 2004-09-02 The Rockefeller University Nucleotide and protein sequences of coc genes and methods based thereon

Similar Documents

Publication Publication Date Title
JP2008500373A5 (https=)
CN112292144B (zh) 激活素受体iib型变体及其使用方法
US10730936B2 (en) Engineered anti-TGF-β antibodies and antigen-binding fragments
ES2361269T3 (es) Anticuerpos especificos de tgf beta 1.
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
CA3009650A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
US11484573B2 (en) Activin receptor type IIa variants and methods of use thereof
JP7250706B2 (ja) 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
AU2012205384B2 (en) IL-27 antagonists for treating inflammatory diseases
EP2305715A2 (en) Monoclonal antibody to osteoprotegerin binding protein
US20190282663A1 (en) Activin receptor type iia variants and methods of use thereof
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
EA021425B1 (ru) Мутанты fgf21 и их применение
CN110177564A (zh) 多价的调节t细胞调节剂
MX2013010011A (es) Agentes de unión biespecífica.
JP2021533204A5 (https=)
JP2009545313A5 (https=)
JP2018538356A (ja) 組織修復のための二重特異性治療用タンパク質
CN118159557A (zh) Sars-cov-2棘蛋白特异性抗体及其用途
TW201425339A (zh) 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物
AU2016332062A1 (en) Treatment of bile acid disorders
US12329801B2 (en) Regenerative polypeptides and uses thereof
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
AU2007332819A1 (en) Uses of cerberus, coco and derivatives thereof
CN107531798A (zh) Pcsk9的抑制剂用于脂蛋白代谢病症的治疗